Iqra Nadeem
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Iqra Nadeem has a total of 18 co-authors. Here are the top co-authors by number of shared publications:
- Abiola Abdulrahman Ayanlaja
Department of Neurology, Johns Hopkins University School of Medicine, 201 N Broadway, Baltimore, MD 21287, USA
1 shared publication - Dianshuai Gao
Public Experimental Research Center, Department of Neurobiology and Anatomy, Xuzhou Medical University, Xuzhou, China
1 shared publication - Guo Xiaoxiao
Department of Basic Medicine, Kangda College of Nanjing Medical University, Lianyungang 222000, China
1 shared publication - Heather Friberg
Viral Diseases Branch, Walter Reed Army Institute of Research, Silver Spring, Maryland, USA
1 shared publication - Jeffrey R. Currier
Viral Diseases Branch, Walter Reed Army Institute of Research , Silver Spring, Maryland
1 shared publication Jessica Bolton
Walter Reed Army Inst. of Res
1 shared publication
Latest Publications
- Open Access
- 27 February 2025
- Vol. 2 (1)
Gut Dysbiosis in Alzheimer’s Disease Pathogenesis and Therapeutic Implications
- 27 February 2025
- Vol. 2 (1)
Open AccessGut Dysbiosis in Alzheimer’s Disease Pathogenesis and Therapeutic Implications
- Open Access
- 27 February 2025
- Published by Premier Science in Premier Journal of Neuroscience
- Vol. 2 (1)
Gut Dysbiosis in Alzheimer’s Disease Pathogenesis and Therapeutic Implications
Alzheimer’s disease (AD) is a type of neurodegenerative disease that is characterized by cognitive decline, memory loss, and the deposition of amyloid plaques and tau tangles in the brain. Although the pathogenesis of AD has traditionally been connected to genetic, environmental, and neurobiological factors, the role of the gut microbiota in AD progression remains unclear. Dysregulation of gut microbiota—dysbiosis—may lead to imbalances in microbial diversity and metabolite production, which directly affect the development and progression of AD. This study reviews the relationship between gut dysbiosis and AD, focusing on therapeutic interventions targeting gut microbiota, including prebiotics, probiotics, and fecal microbiota transplantation. We discuss the novel mechanisms by which microbial metabolites, immune activation, and gut-derived signals can exacerbate AD symptoms. Additionally, we highlight the theoretical potential of microbiome editing using CRISPR-Cas9 as a future novel approach to address dysbiosis in AD. By advancing the understanding of the role of dysbiosis in AD, this review proposes a research direction to address existing gaps and facilitate the development of microbiome-based therapeutic strategies.
- 27 February 2025
- Published by Premier Science in Premier Journal of Neuroscience
- Vol. 2 (1)
Open AccessGut Dysbiosis in Alzheimer’s Disease Pathogenesis and Therapeutic Implications
Alzheimer’s disease (AD) is a type of neurodegenerative disease that is characterized by cognitive decline, memory loss, and the deposition of amyloid plaques and tau tangles in the brain. Although the pathogenesis of AD has traditionally been connected to genetic, environmental, and neurobiological factors, the role of the gut microbiota in AD progression remains unclear. Dysregulation of gut microbiota—dysbiosis—may lead to imbalances in microbial diversity and metabolite production, which directly affect the development and progression of AD. This study reviews the relationship between gut dysbiosis and AD, focusing on therapeutic interventions targeting gut microbiota, including prebiotics, probiotics, and fecal microbiota transplantation. We discuss the novel mechanisms by which microbial metabolites, immune activation, and gut-derived signals can exacerbate AD symptoms. Additionally, we highlight the theoretical potential of microbiome editing using CRISPR-Cas9 as a future novel approach to address dysbiosis in AD. By advancing the understanding of the role of dysbiosis in AD, this review proposes a research direction to address existing gaps and facilitate the development of microbiome-based therapeutic strategies.
- Open Access
- 1 May 2023
- Published by Oxford University Press (OUP) in The Journal of Immunology
- Vol. 210 (Supplement) , 246.10
Analysis of T Cell Immunity Generated by Takeda’s Tetravalent Dengue Vaccine
Dengue is a viral disease transmitted to humans through the bite of infected mosquitoes and is caused by dengue virus (DENV), which has four distinct serotypes, DENV1 to DENV4. Severe dengue is a leading cause of serious illness and death in some Asian and Latin American countries. The Walter Reed Army Institute of Research (WRAIR) has been working to investigate the cell mediated immunogenicity of Takeda’s live attenuated virus tetravalent dengue vaccine (TAK-003). Previously, we have used ELISPOT and Flow-ICS assays to show that TAK-003 induces a robust IFN-γ producing DENV-specific T cell response that is durable to at least 6 months post-vaccination. In addition, this response is mediated by both CD8+ and CD4+ T cells that produce IFN-γ and/or TNFα and IL-2. Using samples from a phase II study, DEN-313 (NCT02948829) conducted in healthy children aged 4 to 16 years in dengue endemic locations, herewith we extend the findings on TAK-003 induced DENV-specific T cell responses to: (1) present data on durability of the CMI response through 3 years post-vaccination; (2) verify the serotype coverage of the T cell response; (3) assess multifunctional capacity of the durable memory T cells, and (4) describe the phenotypic changes that occur among these cells based upon central memory (CD45RA−/CCR7+), effector memory (CD45RA−/CCR7−) and effector memory RA phenotyping (CD45RA+/CCR7−). Our data describe the frequency, functionality, and memory phenotype of T cells induced by TAK-003 up to 3 years post vaccination. Finding received through corporative research and development agreement with Takeda vaccine company.
- 1 May 2023
- Published by Oxford University Press (OUP) in The Journal of Immunology
- Vol. 210 (Supplement) , 246.10
Open AccessAnalysis of T Cell Immunity Generated by Takeda’s Tetravalent Dengue Vaccine
Dengue is a viral disease transmitted to humans through the bite of infected mosquitoes and is caused by dengue virus (DENV), which has four distinct serotypes, DENV1 to DENV4. Severe dengue is a leading cause of serious illness and death in some Asian and Latin American countries. The Walter Reed Army Institute of Research (WRAIR) has been working to investigate the cell mediated immunogenicity of Takeda’s live attenuated virus tetravalent dengue vaccine (TAK-003). Previously, we have used ELISPOT and Flow-ICS assays to show that TAK-003 induces a robust IFN-γ producing DENV-specific T cell response that is durable to at least 6 months post-vaccination. In addition, this response is mediated by both CD8+ and CD4+ T cells that produce IFN-γ and/or TNFα and IL-2. Using samples from a phase II study, DEN-313 (NCT02948829) conducted in healthy children aged 4 to 16 years in dengue endemic locations, herewith we extend the findings on TAK-003 induced DENV-specific T cell responses to: (1) present data on durability of the CMI response through 3 years post-vaccination; (2) verify the serotype coverage of the T cell response; (3) assess multifunctional capacity of the durable memory T cells, and (4) describe the phenotypic changes that occur among these cells based upon central memory (CD45RA−/CCR7+), effector memory (CD45RA−/CCR7−) and effector memory RA phenotyping (CD45RA+/CCR7−). Our data describe the frequency, functionality, and memory phenotype of T cells induced by TAK-003 up to 3 years post vaccination. Finding received through corporative research and development agreement with Takeda vaccine company.
- 28 January 2021
- Published by Springer Nature in Metabolic Brain Disease
- Vol. 36 (4) , 609-625
The orphan nuclear receptor Nurr1 agonist amodiaquine mediates neuroprotective effects in 6-OHDA Parkinson’s disease animal model by enhancing the phosphorylation of P38 mitogen-activated kinase but not PI3K/AKT signaling pathway
Recent studies implicate the defects or altered expression of the orphan nuclear receptor Nurr1 gene in the substantia nigra in Parkinson’s disease pathogenesis. In an attempt to corroborate the treatment-modifying disease that would replicate the effect of Nurr1, it has been found that amodiaquine and Nurr1 had the same chemical scaffolding, indicating a crucial structure-activity relationship. Interestingly, amodiaquine stimulate the transcriptional function of Nurr1 by physical interaction with its ligand-binding domain (LBD). However, the signaling route by which Nurr1 is activated by amodiaquine to cause the protective effect remains to be elucidated. We first demonstrated that amodiaquine treatment ameliorated behavioural deficits in 6-OHDA Parkinson’s disease mouse model, and it promoted dopaminergic neurons protection signified by Tyrosine hydroxylase (TH) and dopamine transporter (DAT) mRNA; Tyrosine hydroxylase (TH) protein expression level and the immunoreactivity in the substantia nigra compacta. Subsequently, we used inhibitors to ascertain the effect of amodiaquine on Akt and P38 Mapk as crucial signaling pathways for neuroprotection. Wortmannin (Akt Inhibitor) induced a significant reduction of Akt mRNA; however, there was no statistical difference between the amodiaquine-treated group and the control group suggesting that amodiaquine may not be the active stimulant of Akt. Western blot analysis confirmed that the phosphorylated Akt decreased significantly in the amodiaquine group compared to the control group. In the same vein, we found that amodiaquine substantially increased the level of phosphorylated P38 Mapk. When P38 Mapk inhibited by SB203580 (P38-Mapk Inhibitor), the total P38 Mapk but not the phosphorylated P38 Mapk decreased significantly, while tyrosine hydroxylase significantly increased. These results collectively suggest that amodiaquine can augment tyrosine hydroxylase expression via phosphorylated P38 Mapk while negatively regulating the phosphorylated Akt in protein expression.
- 28 January 2021
- Published by Springer Nature in Metabolic Brain Disease
- Vol. 36 (4) , 609-625
The orphan nuclear receptor Nurr1 agonist amodiaquine mediates neuroprotective effects in 6-OHDA Parkinson’s disease animal model by enhancing the phosphorylation of P38 mitogen-activated kinase but not PI3K/AKT signaling pathway
Recent studies implicate the defects or altered expression of the orphan nuclear receptor Nurr1 gene in the substantia nigra in Parkinson’s disease pathogenesis. In an attempt to corroborate the treatment-modifying disease that would replicate the effect of Nurr1, it has been found that amodiaquine and Nurr1 had the same chemical scaffolding, indicating a crucial structure-activity relationship. Interestingly, amodiaquine stimulate the transcriptional function of Nurr1 by physical interaction with its ligand-binding domain (LBD). However, the signaling route by which Nurr1 is activated by amodiaquine to cause the protective effect remains to be elucidated. We first demonstrated that amodiaquine treatment ameliorated behavioural deficits in 6-OHDA Parkinson’s disease mouse model, and it promoted dopaminergic neurons protection signified by Tyrosine hydroxylase (TH) and dopamine transporter (DAT) mRNA; Tyrosine hydroxylase (TH) protein expression level and the immunoreactivity in the substantia nigra compacta. Subsequently, we used inhibitors to ascertain the effect of amodiaquine on Akt and P38 Mapk as crucial signaling pathways for neuroprotection. Wortmannin (Akt Inhibitor) induced a significant reduction of Akt mRNA; however, there was no statistical difference between the amodiaquine-treated group and the control group suggesting that amodiaquine may not be the active stimulant of Akt. Western blot analysis confirmed that the phosphorylated Akt decreased significantly in the amodiaquine group compared to the control group. In the same vein, we found that amodiaquine substantially increased the level of phosphorylated P38 Mapk. When P38 Mapk inhibited by SB203580 (P38-Mapk Inhibitor), the total P38 Mapk but not the phosphorylated P38 Mapk decreased significantly, while tyrosine hydroxylase significantly increased. These results collectively suggest that amodiaquine can augment tyrosine hydroxylase expression via phosphorylated P38 Mapk while negatively regulating the phosphorylated Akt in protein expression.